Cargando…

Growing Evidence Linking Microvascular Dysfunction With Heart Failure With Preserved Ejection Fraction

Detalles Bibliográficos
Autores principales:	Giamouzis, Gregory, Schelbert, Erik B., Butler, Javed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802456/ https://www.ncbi.nlm.nih.gov/pubmed/26908416 http://dx.doi.org/10.1161/JAHA.116.003259

Ejemplares similares

Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
por: D’Amario, Domenico, et al.
Publicado: (2019)

Coronary microvascular dysfunction and heart failure with preserved ejection fraction: what are the mechanistic links?
por: Sinha, Aish, et al.
Publicado: (2023)

The Role of Systemic Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction
por: Weerts, Jerremy, et al.
Publicado: (2022)

Untangling the pathophysiologic link between coronary microvascular dysfunction and heart failure with preserved ejection fraction
por: Sinha, Aish, et al.
Publicado: (2021)

Heart failure with preserved ejection fraction: A distinct heart failure phenotype?
por: Triposkiadis, Filippos, et al.
Publicado: (2022)

Microvascular Rarefaction and Heart Failure With Preserved Ejection Fraction
por: Zeng, Heng, et al.
Publicado: (2019)

Estrogen Contributions to Microvascular Dysfunction Evolving to Heart Failure With Preserved Ejection Fraction
por: Sickinghe, Ariane A., et al.
Publicado: (2019)

Regional differences and coronary microvascular dysfunction in heart failure with preserved ejection fraction
por: Erhardsson, Mikael, et al.
Publicado: (2023)

Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis
por: Bilak, Joanna M, et al.
Publicado: (2022)

Microvascular dysfunction and cardiac fibrosis in heart failure with preserved ejection fraction: a case report
por: Narang, Nikhil, et al.
Publicado: (2017)

Progression of coronary microvascular dysfunction to heart failure with preserved ejection fraction: a case report
por: Joung, Sandy, et al.
Publicado: (2019)

Coronary Microvascular Dysfunction and Heart Failure with Preserved Ejection Fraction - implications for Chronic Inflammatory Mechanisms
por: Fopiano, Katie Anne, et al.
Publicado: (2022)

Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction
por: Talha, Khawaja M., et al.
Publicado: (2022)

Endothelial-cell-mediated mechanism of coronary microvascular dysfunction leading to heart failure with preserved ejection fraction
por: Wang, Yong, et al.
Publicado: (2022)

Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction
por: Chandramouli, Chanchal, et al.
Publicado: (2022)

Heart failure with reduced, mildly reduced, or preserved left ventricular ejection fraction: Has reasoning been lost?
por: Xanthopoulos, Andrew, et al.
Publicado: (2022)

The utility of cardiovascular imaging in heart failure with preserved ejection fraction: diagnosis, biological classification and risk stratification
por: Lewis, Gavin A., et al.
Publicado: (2020)

The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction
por: Sandesara, Pratik B., et al.
Publicado: (2018)

Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 diabetes
por: Mordi, Ify R., et al.
Publicado: (2020)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

Heart Failure With Preserved Ejection Fraction: An Evolving Understanding
por: Tah, Sunanda, et al.
Publicado: (2023)

Predictors of myocardial fibrosis and response to anti-fibrotic therapy in heart failure with preserved ejection fraction
por: Lewis, Gavin A., et al.
Publicado: (2022)

Diastolic dysfunction in individuals with and without heart failure with preserved ejection fraction
por: Wenzel, Jan-Per, et al.
Publicado: (2021)

NADPH Oxidases in Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction
por: Teuber, James P., et al.
Publicado: (2022)

Pirfenidone in Heart Failure with Preserved Ejection Fraction—Rationale and Design of the PIROUETTE Trial
por: Lewis, Gavin A., et al.
Publicado: (2019)

Impact of Myocardial Fibrosis on Cardiovascular Structure, Function and Functional Status in Heart Failure with Preserved Ejection Fraction
por: Lewis, Gavin A., et al.
Publicado: (2022)

Characteristics Associated With Growth Differentiation Factor 15 in Heart Failure With Preserved Ejection Fraction and the Impact of Pirfenidone
por: Lewis, Gavin A., et al.
Publicado: (2022)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

Management of heart failure with preserved ejection fraction
por: Gard, Emma, et al.
Publicado: (2020)

Managing heart failure with preserved ejection fraction
por: Davidson, Alexander, et al.
Publicado: (2020)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Comorbidities in heart failure with preserved ejection fraction
por: Deichl, Andrea, et al.
Publicado: (2022)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Endothelial Dysfunction in Heart Failure With Preserved Ejection Fraction: What are the Experimental Proofs?
por: Cornuault, Lauriane, et al.
Publicado: (2022)

Myocardial strain for heart failure with preserved ejection fraction but without diastolic dysfunction
por: Park, Jin Joo, et al.
Publicado: (2022)

Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
por: Packer, Milton, et al.
Publicado: (2021)

Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
por: Butler, Javed, et al.
Publicado: (2022)

The Molecular and Cellular Mechanisms Associated with a Microvascular Inflammation in the Pathogenesis of Heart Failure with Preserved Ejection Fraction
por: Ovchinnikov, A. G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uhs2158u17pr3nquo7e9qk9k3k